(27 days)
The TracStar LDP Large Distal Platform is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
The Zoom 88 Large Distal Platform and Zoom 88 Large Distal Platform Support are indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
The Imperative Care Large Distal Platform (LDP) Catheters include the Zoom™ 88 Large Distal Platform, Zoom™ 88 Large Distal Platform Support, and TracStar™ LDP Large Distal Platform. The LDP Catheters are 0.038" diameter or smaller guidewire compatible single lumen guide catheters that provide access to peripheral, coronary and neuro vasculature. The catheters are comprised of a hollow cylindrical tube bonded at the proximal end to a standard luer fitting. The wall of the tube is constructed using a combination of metal coils/braids and medical grade polymers. The distal section of each catheter has a hydrophilic coating to enhance tracking through tortuous vasculature. An angled distal soft tip facilitates smooth tracking past vessel branches. A radiopaque marker provides visual confirmation of the distal tip location under fluoroscopy. LDP Catheters have an inner diameter of 0.088" (6F compatible), and a maximum outer diameter of 0.110". The LDP guide catheters are packaged with a rotating hemostasis valve (RHV) that is attached to the proximal luer to help maintain hemostasis.
This FDA 510(k) Summary describes a device (TracStar LDP Large Distal Platform, Zoom 88 Large Distal Platform, Zoom 88 Large Distal Platform Support) intended for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature. The submission is for a line extension and manufacturing process improvements, referencing a predicate device (K212224). Therefore, the study details provided are focused on demonstrating substantial equivalence to the predicate device, rather than a de novo clinical trial for a new product with absolute performance metrics against a disease state.
Here's a breakdown of the requested information based on the provided document:
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria for this 510(k) submission are based on the performance of the device against a set of predefined specifications derived from an existing standard (ISO 10555-1 for catheter performance) and internal engineering requirements. The reported device performance is simply "Pass" for all tested attributes, indicating that the subject device met these specifications.
| Test Attribute | Acceptance Criteria | Reported Device Performance |
|---|---|---|
| Delivery, Compatibility, and Retraction (Trackability) | The catheter shall be able to be delivered, deployed, and retracted per the IFU within a simulated neurological model without incurring any damage to the catheter. | Pass |
| Flexibility and Kink Resistance | There shall be no kinking of shaft (permanent deformation) after simulated use. | Pass |
| Compatibility with other Devices (external) | The catheters shall be able to be delivered through the minimum introducer sheath or guide catheter size indicated in the product labeling. | Pass |
| Guidewire Compatibility | The catheters shall be able to be delivered over the maximum size guidewire indicated in the product labeling. | Pass |
| Interventional Device Compatibility (internal) | The catheters shall be able to accommodate other interventional devices (e.g., support catheter, diagnostic catheter) up to the maximum size indicated in the product labeling. | Pass |
| Luer Compatibility | Devices and accessories shall be compatible with standard syringe luer fittings per ISO 80369-7. | Pass |
| Accessory Compatibility | Devices shall be compatible with an RHV. | Pass |
| Catheter Bond Strength | The catheter shall have sufficient bond strengths to remain intact throughout a procedure. | Pass |
| Dimensional (Distal ID, Proximal ID, Distal OD, Proximal OD) | All defined catheter dimensions are within the specified tolerances. | Pass |
| Catheter Torque Strength | With the catheter tip held in a static position, there shall be no separation of any portion of the catheter when rotated at the hub at least two (2) full rotations (720 degrees). | Pass |
| Coating - Particulate and Integrity | The amount of particulate matter generated during simulated use testing shall be determined and compared to competitive products and techniques. There were no coating anomalies or significant wear observed post simulated use. | Pass |
| Coating – Lubricity and Durability | Coating must be lubricious with a specified average pull force. | Pass |
2. Sample Size Used for the Test Set and Data Provenance
The document does not specify the exact sample sizes used for each bench and laboratory test. It states that "Bench and laboratory (in-vitro) testing was completed" and references "simulated neurological model" and "simulated use testing," indicating an in-vitro experimental setting.
Data Provenance: The data is generated from in-vitro bench and laboratory testing conducted by the manufacturer, Imperative Care, Inc. The country of origin of this data is not explicitly stated, but it is implied to be internal testing. The data is retrospective in the sense that it evaluates the performance of the manufactured devices against pre-established specifications.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
This type of information is not applicable to this 510(k) submission. "Ground truth" established by experts (e.g., radiologists) is typically relevant for studies validating diagnostic or AI-driven devices against clinical outcomes or expert interpretation, such as in an MRMC study. This submission focuses on the physical and mechanical performance of a medical device (catheter) through bench testing.
4. Adjudication Method for the Test Set
Since the evaluation is based on objective measurements and predefined specifications in bench testing (e.g., absence of kinking, passage through a simulated model), there is no adjudication method as typically understood in clinical or expert-reviewed studies. The "Pass/Fail" results are determined by whether the device meets the quantitative and qualitative requirements of the test specifications.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done, If So, What was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance
No, an MRMC comparative effectiveness study was not done. This submission is for a percutaneous catheter, not an AI-driven or diagnostic device that involves human reader interpretation. Consequently, there is no discussion of human reader improvement with or without AI assistance.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done
No, a standalone algorithm performance study was not done. This device is a physical medical instrument (catheter), not a software algorithm.
7. The Type of Ground Truth Used (expert consensus, pathology, outcomes data, etc.)
The "ground truth" in this context refers to the pre-established physical and mechanical performance specifications laid out in the test attributes and derived from standards like ISO 10555-1 and internal engineering requirements. It is a benchmark of expected functional performance, rather than a clinical or pathological diagnosis.
8. The Sample Size for the Training Set
This question is not applicable as this is not a machine learning or AI-driven device. There is no concept of a "training set" for physical device performance testing.
9. How the Ground Truth for the Training Set was Established
This question is not applicable as this is not a machine learning or AI-driven device.
{0}------------------------------------------------
May 22, 2023
Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health and Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
Imperative Care, Inc. Shivani Patel Principal Regulatory Affairs Specialist 1359 Dell Avenue, Campbell, California 95008
Re: K231168
Trade/Device Name: TracStar LDP Large Distal Platform; Zoom 88 Large Distal Platform; Zoom 88 Large Distal Platform Support Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: QJP, DQY Dated: April 24, 2023 Received: April 25, 2023
Dear Shivani Patel:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
{1}------------------------------------------------
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Naira Muradyan -S
Naira Muradyan, Ph.D. Assistant Director DHT5A: Division of Neurosurgical, Neurointerventional and Neurodiagnostic Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K231168
Device Name TracStar™ LDP Large Distal Platform™ Zoom™ 88 Large Distal Platform™ Zoom™ 88 Large Distal Platform™ Support
Indications for Use (Describe)
The TracStar LDP Large Distal Platform is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
The Zoom 88 Large Distal Platform and Zoom 88 Large Distal Platform Support are indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
| Type of Use (Select one or both, as applicable) | ||
|---|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) Summary
A. Submitter Information
Submitter's Name: Address:
Contact Person: Telephone: Email: Date of Preparation:
B. Subject Device
Proprietary Names:
Common/Usual Name: Classification Name: Product Code:
Regulation:
C. Predicate Device(s)
Proprietary Name:
Common/Usual Name: Classification Name: Product Code:
Regulation: Manufacturer: 510(k):
Imperative Care, Inc. 1359 Dell Avenue Campbell, CA 95008 Shivani Patel 510-468-8862 spatel(@imperativecare.com May 19, 2023
TracStar™ LDP Large Distal Platform™ Zoom™ 88 Large Distal Platform™ Zoom™ 88 Large Distal Platform™ Support Guide Catheter Catheter, Percutaneous, Neurovasculature OJP DQY 21 CFR 870.1250
TracStar™ LDP Large Distal Platform Zoom™ 88 Large Distal Platform Guide Catheter Catheter, Percutaneous, Neurovasculature QJP DOY 21 CFR. 870.1250 Imperative Care Inc. K212224
D. Device Description:
The Imperative Care Large Distal Platform (LDP) Catheters include the Zoom™ 88 Large Distal Platform, Zoom™ 88 Large Distal Platform Support, and TracStar™ LDP Large Distal Platform. The LDP Catheters are 0.038" diameter or smaller guidewire compatible single lumen guide catheters that provide access to peripheral, coronary and neuro vasculature. The catheters are comprised of a hollow cylindrical tube bonded at the proximal end to a standard luer fitting. The wall of the tube is constructed using a combination of metal coils/braids and medical grade polymers. The distal section of each catheter has a hydrophilic coating to enhance tracking through tortuous vasculature. An angled distal soft tip facilitates smooth tracking past vessel branches. A radiopaque marker
{4}------------------------------------------------
provides visual confirmation of the distal tip location under fluoroscopy. LDP Catheters have an inner diameter of 0.088" (6F compatible), and a maximum outer diameter of 0.110". The LDP guide catheters are packaged with a rotating hemostasis valve (RHV) that is attached to the proximal luer to help maintain hemostasis.
Accessory devices required, but not supplied include:
- . Guidewires
- Support/diagnostic catheters .
- Introducer sheaths .
E. Indications for Use:
The TracStar LDP Large Distal Platform is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
The Zoom 88 Large Distal Platform and Zoom 88 Large Distal Platform Support are indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
F. Principles of Operation:
The LDP Catheters may be used with support catheters to assist in accessing the target vasculature. During use, the male luer of the RHV is attached to the proximal luer of the LDP Catheter to create a continuous lumen through the catheter and to the RHV ports. The female luer is typically connected to a saline drip line while the LDP Catheter is advanced through the vasculature. Use of the LDP Catheter relies on standard percutaneous interventional techniques, including access site preparation, introducing the catheter portion of the device, advancing the catheter under fluoroscopy, withdrawing the catheter, and closing the access site.
G. Predicate Comparison:
The predicate devices are the Imperative Care LDP Catheters cleared under K212224. The predicate and subject devices share the same intended use, basic technological characteristics, and the same performance characteristics, demonstrated through bench and laboratory testing as shown in Table 1. Modifications to the predicate include minor dimensional modifications for a line extension and manufacturing process improvements.
{5}------------------------------------------------
| Device Attribute | Predicate device | Subject device |
|---|---|---|
| FDA ProductClassification | Class II, QJP andDQY, 21 CFR 870.1250 | Class II, QJP andDQY, 21 CFR 870.1250 |
| Product Name | TracStar LDP Large Distal• PlatformZoom 88 Large Distal• Platform | TracStar LDP Large Distal• PlatformZoom 88 Large Distal• PlatformZoom 88 Large Distal• Platform Support |
| 510(k) Number | K212224 | K231168 |
| Indications for Use | TracStar LDP Large DistalPlatform:The TracStar LDP Large DistalPlatform is indicated for theintroduction of interventionaldevices into the peripheral,coronary, and neuro vasculature.Zoom 88 Large Distal Platform:The Zoom 88 Large DistalPlatform is indicated for theintroduction of interventionaldevices into the peripheral,coronary, and neuro vasculature. | TracStar LDP Large DistalPlatform:SameZoom 88 Large Distal Platformand Zoom 88 Large DistalPlatform Support:The Zoom 88 Large DistalPlatform and Zoom 88 LargeDistal Platform Support areindicated for the introduction ofinterventional devices into theperipheral, coronary, and neurovasculature. |
| Condition Supplied | Sterile and Single Use | Same |
| Sterilization Method | Ethylene Oxide (EtO), SAL 10-6 | Same |
| Inner Diameter(ID, Distal) | 0.088" | Same |
| Outer Diameter(OD, Distal) | 0.106" | Same |
| Inner Diameter(ID, Proximal) | 0.088" | Same |
| Outer Diameter(OD, Proximal) | 0.110" | Same |
| Effective Length | TracStar LDP: 80, 90, 95, 105 cmZoom 88 LDP: 100 cm, 110 cm | TracStar LDP: Same• Zoom 88 LDP: Same• Zoom 88 LDP Support:• 100 cm |
| Device Attribute | Predicate device | Subject device |
| Tip Design | Beveled distal edge, soft, flexible, atraumatic tip | Same |
| Distal Catheter Shaft | Reinforced with metals and polymers | ● TracStar LDP: Same● Zoom 88 LDP: Same● Zoom 88 LDP Support:Same metal reinforcement,modified polymerreinforcement |
| Proximal CatheterShaft | Reinforced with metals and polymers | Same |
| Coating | Hydrophilic coating | Same |
| Materials | Commonly used medical gradeplastics & metals with hydrophiliccoating | Same |
| PackagedAccessories | Rotating Hemostasis Valve (RHV) | Same |
| PackagingConfiguration | The catheters are placed in aprotective polyethylene tube,mounted with accessory RHV ontoa polyethylene packaging card,placed into a pouch, sealed andlabeled. The sealed pouch and IFUare placed in a labeled shelf cartonbox. | Same |
Table 1: Comparison of Subject and Predicate Device
{6}------------------------------------------------
H. Performance Data Supporting Substantial Equivalence:
Bench and laboratory (in-vitro) testing was completed to evaluate the differences between the subject LDP Catheters and predicate LDP Catheters. Performance specifications and test methods were based primarily on catheter performance standard ISO 10555-1 and a summary of the evaluated performance specifications is presented in Table 2.
The test results were reviewed and found to demonstrate that the differences between the subject LDP Catheters and predicate LDP Catheters do not significantly impact any performance parameters that would negatively affect the safety or effectiveness of the subject LDP Catheters.
{7}------------------------------------------------
| Test Attribute | Specification | Results |
|---|---|---|
| Delivery, Compatibility,and Retraction(Trackability) | The catheter shall be able to be delivered,deployed, and retracted per the IFU within asimulated neurological model withoutincurring any damage to the catheter. | Pass |
| Flexibility and KinkResistance | There shall be no kinking of shaft(permanent deformation) after simulateduse. | Pass |
| Compatibility with otherDevices (external) | The catheters shall be able to be deliveredthrough the minimum introducer sheath orguide catheter size indicated in the productlabeling. | Pass |
| GuidewireCompatibility | The catheters shall be able to be deliveredover the maximum size guidewire indicatedin the product labeling. | Pass |
| Interventional DeviceCompatibility (internal) | The catheters shall be able to accommodateother interventional devices (e.g., supportcatheter, diagnostic catheter) up to themaximum size indicated in the productlabeling. | Pass |
| Luer Compatibility | Devices and accessories shall be compatiblewith standard syringe luer fittings per ISO80369-7. | Pass |
| Accessory Compatibility | Devices shall be compatible with an RHV. | Pass |
| Catheter Bond Strength | The catheter shall have sufficient bondstrengths to remain intact throughout aprocedure. | Pass |
| Dimensional (Distal ID,Proximal ID, Distal OD,Proximal OD) | All defined catheter dimensions are withinthe specified tolerances | Pass |
| Catheter TorqueStrength | With the catheter tip held in a staticposition, there shall be no separation of anyportion of the catheter when rotated at thehub at least two (2) full rotations (720degrees). | Pass |
| Coating - Particulateand Integrity | The amount of particulate matter generatedduring simulated use testing shall bedetermined and compared to competitiveproducts and techniques. There were nocoating anomalies or significant wearobserved post simulated use. | Pass |
{8}------------------------------------------------
| Test Attribute | Specification | Results |
|---|---|---|
| Coating – Lubricity andDurability | Coating must be lubricious with a specified average pull force. | Pass |
I. Biocompatibility Testing:
There are no changes to patient contacting materials compared to the predicate device. Therefore, the original testing on the predicate devices applies to the subject devices and additional biocompatibility testing was not required.
J. Sterilization:
The LDP Catheters are sterilized using a validated EtO process with a sterility assurance level of 1x10 6 validated per the overkill method in accordance with ISO 11135. "Sterilization Of Health-Care Products - Ethylene Oxide - Requirements For The Development, Validation And Routine Control Of A Sterilization Process For Medical Devices".
K. Shelf Life and Packaging:
Accelerated aging testing based on ASTM F1980 was previously conducted to verify packaged device performance of the predicate LDP Catheters. The subject LDP Catheters undergo the same packaging and sterilization processing as the predicate LDP Catheters. The new Zoom 88 Large Distal Platform Support Catheter has the same general design, the same raw materials, manufacturing processes and manufacturing aids as the predicate LDP Catheters. Verification testing of the subject LDP Catheters followed the same test methods as the predicate LDP Catheters. Therefore, aging data from the predicate LDP Catheters is applicable for the subject LDP Catheters and additional shelf-life testing was not required.
There are no changes to the packaging compared to the predicate LDP Catheters. Therefore, the original testing on the predicate LDP Catheters applies to the subject LDP Catheters and additional packaging validation testing was not required.
L. Conclusions:
Where differences were identified between the subject and predicate devices, a risk assessment was completed to determine if the difference would result in new safety or effectiveness concerns. As appropriate, previous bench and laboratory testing was
{9}------------------------------------------------
evaluated for applicability and either the rationale for no impact was documented or verification and validation was repeated as required.
Based on the results of the risk assessments and associated bench and laboratory testing, the subject and predicate devices are substantially equivalent and there are no new safety or effectiveness concerns. The subject device and predicate device share the same intended use, basic technological characteristics, and performance characteristics.
§ 870.1250 Percutaneous catheter.
(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).